Drug intelligence / Profile preview

NYVAC-B

Development stage: Phase 1
Lead developer: Sanofi Pasteur
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NYVAC-B is a replication-deficient poxvirus-based vaccine vector developed for HIV immunization. It expresses Gag, Pol, Nef, and Env proteins from an HIV clade B isolate. The vaccine is administered intramuscularly and has been evaluated in clinical trials for its safety and immunogenicity in HIV-infected patients. Clinical data from the Theravac-01 phase I trial showed that NYVAC-B is safe and highly immunogenic, inducing broad, vigorous, and polyfunctional HIV-specific T-cell responses in virtually all vaccinees.

Beyond the preview

Go deeper on NYVAC-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NYVAC-B.

Explore the full profile